Lyra’s transmucosal therapeutic system, now being evaluated in a clinical study, is designed to directly target tissues that are difficult or impossible to access with existing therapies.
Our first product candidate is designed to address chronic rhinosinusitis (CRS), which affects about 27 million – 11% of adults – in the U.S., and has no approved pharmaceutical treatments.
We are working to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.
October 8, 2018
Lyra Therapeutics Presents Clinical Data for LYR-210 for Treatment of Chronic Rhinosinusitis at the American Rhinologic Society Annual Meeting